Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2Phase NA 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 870Carcinoma, Non-Small-Cell Lung 637Prostatic Neoplasms 516Multiple Myeloma 443Neoplasms 425Leukemia, Myeloid, Acute 380Lymphoma 357Melanoma 335Leukemia 335Neoplasm Metastasis 322Lung Neoplasms 308Lymphoma, Non-Hodgkin 303Leukemia, Lymphocytic, Chronic, B-Cell 301Colorectal Neoplasms 282Ovarian Neoplasms 266Pancreatic Neoplasms 249Precursor Cell Lymphoblastic Leukemia-Lymphoma 241Recurrence 240Myelodysplastic Syndromes 233Glioblastoma 212Hodgkin Disease 201Lymphoma, Large B-Cell, Diffuse 197Lymphoma, Follicular 195Brain Neoplasms 195Carcinoma, Renal Cell 190Head and Neck Neoplasms 188Squamous Cell Carcinoma of Head and Neck 186Lymphoma, Mantle-Cell 171Sarcoma 158Fallopian Tube Neoplasms 139

Interventions

folfirinox 1Radiotherapy 1PEGPH20 1Gemcitabine 1Enoxaparin 1Dexamethasone 1Capecitabine 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Has results × Carcinoma, Pancreatic Ductal × Clear all
NCT01839487 2020-07-20

PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer

Halozyme Therapeutics

Phase 2 Completed
279 enrolled 19 charts
Gastrointestinal

Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal

NCT02243007 2017-05-16

Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer

Massachusetts General Hospital

Phase 2 Terminated
7 enrolled 8 charts
Gastrointestinal

Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡